Hot Products

Karavilagenin D
Catalog No: CFN97506

Karavilagenin D exhibits inhibitory effects on skin-tumor promotion in an in vivo two-stage mouse skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator, and with TPA as a promoter. It exhibits inhibition effect against human cancer cell lines.

Karounidiol
Catalog No: CFN90563

Karounidiol exhibits cytotoxicity especially against a human renal cancer, it markedly suppresses the promoting effect of TPA (1 microgram/mouse) on skin tumor formation in mice following initiation with 7,12-dimethylbenz[a]anthracene (50 micrograms/mouse).

Kaurenoic acid
Catalog No: CFN97703

Kaurenoic acid has anti-inflammatory, analgesic, antimicrobial, cytotoxic and embryotoxic effects; it exerts a uterine relaxant effect acting principally through calcium blockade and in part, by the opening of ATP-sensitive potassium channels. Kaurenoic acid involves the inhibition of cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.

Kawain
Catalog No: CFN92656

Kavain has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels. Kawain is advanced glycation endproduct inhibitors, can increase the mean life span of Caenorhabditis elegans exposed to high glucose.

Kazinol A
Catalog No: CFN92431

Kazinol A shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation. It also exhibits potent inhibition with IC50 values ranging 0.6–164 M against XOD. Kazinol A may be a candidate for the development of effective anti-cancer drug on human urinary bladder cancer, it induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2.

Kazinol B
Catalog No: CFN97569

Kazinol B inhibits the NO synthesis with an IC(50) of 21.6 microM. It can stimulate respiratory burst, is probably mediated by the synergism of PKC activation and [Ca2+]i elevation in rat neutrophils. Kazinol B stimulates Ca(2+) release from internal Ca(2+) store, probably through the sphingosine 1-phosphate and IP(3) signaling, and activates external Ca(2+) influx mainly through a non-store-operated Ca(2+) entry (non-SOCE) pathway. Kazinol B improves insulin sensitivity via Akt and AMPK activation in 3T3-L1 adipocytes, it might be a therapeutic candidate for diabetes mellitus.

Kazinol U
Catalog No: CFN97839

Kazinol U may have therapeutic value in delaying pancreatic β-cell destruction in type 1 diabetes by blocking the NF-κB pathway in pancreatic β-cells reduces cell damage. Kazinol U shows estrogenic activity with ligand-activity of estrogen receptor, transcriptional activity of estrogen -responsive element-reporter genes, it may have beneficial effects in the treatment of menopausal symptoms.

Khasianine
Catalog No: CFN90387

Khasianine exhibits strong activity against liver damage induced by CCl4.

Khellactone
Catalog No: CFN96394

Khellactone shows antitumor activity,it can suppress the growth of NCI-H460 tumor cells. (+)-4'-cis-Khellactone and (+)-3'-cis-khellactone have antiplasmodial activities, they show notable inhibitory activity against -sensitive strains of with IC(50) values from 1.5 and 2.4 microM.

Khellin
Catalog No: CFN97303

Khellin, as photosensitizer, together with ultraviolet A (UVA) irradiation, it can treat vitiligo patients; it does not induce skin phototoxicity with UVA but it induces repigmentation similar to psoralens. Khellin exhibits significant Epidermal Growth Factor Receptor (EGFR) inhibitory activity, it has anti-inflammatory, and analgesic properties, it may be beneficial in the management of kidney stone disease caused by hyperoxaluria.